Apollomics has articulated a clear vision for the utilization of the net proceeds from this financing round.
Apollomics Inc. (Nasdaq: APLM), a burgeoning force in the clinical-stage biopharmaceutical arena, has recently announced a strategic private investment in public equity (PIPE) financing. This bold step is poised to inject approximately $6 million in gross proceeds into the company, prior to the ded...